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Objective: To examine the effect of Senna alata (S. alata) leaf extracts on the regulation
of lipid metabolism in high-fat diet-induced obese mice.
Methods: The obesity condition was induced in the male ICR mice by feeding them with
high-fat diet (45 kcal% fat) for 12 weeks. At the 7th week of diet feeding, the obese mice
were treated with the water extract of S. alata leaf at 250 and 500 mg/kg/day, respec-
tively, that continued for six weeks. At the end of the treatment period, the biochemical
parameters were determined. The hepatic histology and the gene and protein expressions
were also examined.
Results: In comparison with the obese control mice, the mice treated with S. alata
showed a signiﬁcant reduction in the elevated blood glucose levels and a decrease in the
serum insulin and leptin levels. A reduction in the serum total cholesterol, triglyceride,
non-esteriﬁed fatty acid, and hepatic triglyceride levels were also observed. The histo-
logical examination of the obese mice treated with S. alata showed a reduced lipid
accumulation in the liver tissue. Hepatic lipogenic gene expression showed that S. alata
decreased the activity of sterol regulatory element binding protein 1c, fatty acid synthase,
and acetyl-CoA carboxylase. S. alata could suppress hepatic peroxisome proliferator-
activated receptor gamma (PPARg) protein. Moreover, the protein expression of
PPARa in liver tissue was clearly increased by S. alata treatment.
Conclusion: The treatment with S. alata could decrease several parameters of impaired
lipid metabolism in the obese mice by downregulating sterol regulatory element binding
protein 1c and PPARg and upregulating PPARa. This study is the ﬁrst report on the role
of S. alata leaf extract in alleviating the abnormal lipid metabolism in obese conditions.1. Introduction
Obesity development is a risk factor for inducing the status of
insulin resistance, type 2 diabetes mellitus, fatty liver disease, andcoronary heart disease [1]. Obesity is strongly related to the
nonalcoholic fatty liver disease, a common liver disorder
characterized by increased triglyceride (TG) accumulation in the
liver tissue in the absence of excessive alcohol consumption [2].
Adipose tissue plays an important role in the regulation of
energy homeostasis and development of insulin resistance [3].
The long-term high-fat diet (HFD) feeding can cause adipo-
cyte hypertrophy and its dysfunction. It is characterized by an
elevated release of free fatty acid (FFA) into the liver, causing
increased hepatic FFA inﬂux that is implicated in hepatic insulin
resistance by impaired insulin signaling and increased hepatic
gluconeogenesis. The elevated hepatic FFA inﬂux also stimu-
lates de novo lipogenesis, leading to the precipitation of TG
synthesis that causes hepatic steatosis [4]. The insulin resistance
with a signiﬁcantly high insulin level can stimulate the
transcription factors that regulates hepatic lipogenesis and b-
oxidation of FFA including sterol regulatory element bindingarticle under the CC BY-NC-ND license (http://
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proliferator receptors (PPARs) [5]. SREBP1c plays a key role
in the dietary regulation of lipid metabolism. The activation of
SREBP1c shows an increase in hepatic lipogenesis, leading to
fatty liver under HFD feeding [6]. SREBP1c is related to the
stimulation of the lipogenic enzymes such as fatty acid
synthase (FAS) and acetyl-CoA carboxylase (ACC) [7].
PPARa is predominantly expressed in the liver and helps in
the modulation of the lipid metabolism and maintenance of
energy balance. The increase in the concentration of fatty
acids leads to the activation of PPARa and uptake of fatty
acids in the oxidized form. The oxidation of fatty acids occurs
mainly in the liver, and it prevents steatosis [8]. PPARg is
highly expressed in the adipocytes and further controls the
differentiation and metabolic processes in liver, macrophages,
bone cells, and skeletal muscles [9]. It is also an important
transcription factor that causes increased lipid accumulation in
the liver tissue. The overexpression of PPARg is associated
with increased hepatic steatosis by activation of the lipogenic
genes and lipogenesis, as well as increased TG level [10].
Senna alata (S. alata) is a tropical plant found in many
countries, including Thailand. It exhibits several bioactivities such
as antitumor [11], anthelmintic [12], antibacterial [13], antioxidant
and anti-inﬂammatory [14], and antidiabetic activities [15].
However, there is no report on the effect of S. alata leaf extract
on hepatic lipogenesis in obesity. Therefore, this study was
designed to evaluate the role of the mechanism of S. alata leaf
extract on impaired lipid metabolism in HFD-fed mice.
2. Materials and methods
2.1. Chemicals and reagents
All chemicals were purchased from Sigma–Aldrich (St.
Louis, MO, USA). The low-fat diet (LFD) and HFD were pur-
chased from Research Diets (New Brunswick, NJ, USA). Anti-
PPARa, anti-PPARg, and anti-b actin were purchased from
Santa Cruz Biotechnology, Inc. (Dallas, TX, USA).
2.2. Plant extraction
The S. alata leaves were collected from Buriram, Thailand,
between July and September 2013.A voucher specimen (SKP 034
19 01 01) was given by the Faculty of Pharmaceutical Sciences,
Prince of Songkla University, Thailand. The dried leaves were
extracted three times with water at 100 C for 30 min. This extract
was concentrated and subsequently freeze-dried. The yield ob-
tained was 15.58% of the starting dry weight of the leaves. The
protocol of Sumczynski et al. [16] and Folin–Ciocalteumethod [17]
were used formeasuring the amount of the totalﬂavonoid and total
polyphenol, respectively. The total ﬂavonoid was estimated to be
26.01 ± 3.40 mg catechin/g S. alata extract and the total
polyphenol was 57.50 ± 3.51 mg gallic acid/g S. alata extract.
2.3. Acute toxicity test
Male and female ICR mice weighing 30–35 g were obtained
from the National Laboratory Animal Center of Mahidol Uni-
versity, Nakhon Pathom, Thailand. The animals were divided
into ﬁve groups, ten mice (ﬁve male and ﬁve female) in each
group. Group I received distilled water (control group) and theother groups received S. alata extracts at doses of 250, 500,
1000, and 2000 mg/kg body weight daily for a week. General
behavior, adverse effects and mortality were observed
throughout the experimental period. Body weight and organ
weight were evaluated at the end of all tests.
2.4. Induction of obesity and experimental design
Thirty-two male ICR mice weighing 20–25 g were obtained
from the National Laboratory Animal Center of Mahidol Uni-
versity, Nakhon Pathom, Thailand. All the animal experiments
were approved by the Animal Ethics Committee of Thammasat
University, Pathum Thani, Thailand (Rec. No. AE 009/2014).
The animals were housed under standard conditions with free
access to water and fed with an LFD for one week. Then they
were fed with either LFD containing 10% fat (0.72 mg
cholesterol per gram of lard) with a total energy of 3.85 kcal/g
diets or HFD containing 45% fat (0.72 mg cholesterol per gram
of lard) with a total energy of 4.73 kcal/g for 12 weeks. After six
weeks of diet, the animals were randomly divided into four
groups (n = 8). Group I included normal control (NC) mice who
were fed with LFD; group II included obese control (OB) mice
who were fed with HFD, and groups III and IV included obese
mice treated with S. alata extracts (250 and 500 mg/kg,
respectively) for six weeks. Distilled water was administered to
all the mice. For groups III and IV, the S. alata extracts were
dissolved in the distilled water administered to the mice. The
body weight and food intake of the mice were recorded every
week.
2.5. Collection of blood and tissue samples
After six weeks of the treatment period, the mice were
sacriﬁced using isoﬂurane anesthesia. The whole blood samples
were collected by cardiac puncture for measuring the blood
glucose level, and the remaining blood samples were centrifuged.
The collected serum was kept for biochemical analysis. The liver
tissue was taken for the analysis of pathohistological change, and
the rest of liver was stored at −70 C until further analysis.
2.6. Analysis of biochemical parameters
The fasting serum insulin and leptin concentrations were
determined using ELISA kits (EMD Millipore, MA, USA). The
serum total cholesterol (TC), TG, and non-esteriﬁed fatty acid
(NEFA) were measured using the enzymatic colorimetric kit
(Wako, Osaka, Japan).
2.7. Analysis of hepatic triglyceride
The liver TG was measured using the enzymatic colorimetric
kit (Wako, Osaka, Japan). The protocol for liver TG extraction
was used as described previously [18]. Brieﬂy, 50 mg of the liver
was extracted with 1 mL of isopropanol and then centrifuged to
collect the supernatant for the determination of TG.
2.8. Total RNA extraction and quantitative real-time
polymerase chain reaction
Total RNA was extracted from the liver tissue using TRIzol®
reagent (Life Technologies, CA, USA) and reverse-transcribed to
Table 1
General appearance and behavioral observations of varied doses of
S. alata leaf extracts in normal mice for a week.
Observations S. alata treatment group (mg/kg body weight/
day)
Control 250 500 1000 2000
Skin and fur Normal Normal Normal Normal Normal
Eyes Normal Normal Normal Normal Normal
Mucous membrane Normal Normal Normal Normal Normal
Behavioral patterns Normal Normal Normal Normal Normal
Salivation Normal Normal Normal Normal Normal
Lethargy Normal Normal Normal Normal Normal
Diarrhea Normal Normal Normal Normal Normal
Tremor Normal Normal Normal Normal Normal
Coma None None None None None
Death None None None None None
Control group received distilled water.
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scription kit (Applied Biosystems, CA, USA), according to the
manufacturer's protocol. Then, the RNA expression level was
quantiﬁed by quantitative real-time polymerase chain reaction
(PCR) using TaqMan gene expression master mix kit (Applied
Biosystems, CA, USA) and StepOnePlus™ real-time PCR sys-
tem (Applied Biosystems, CA, USA). The TaqMan probes and
primer sequences for SREBP1c, FAS, ACC, and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) were obtained from
Applied Biosystems (SREBP1c: Mm00550338_m1, FAS:
Mm00662319_m1, ACC: Mm01304257, and GAPDH:
Mm99999915_g1). The relative amounts of all mRNAs were
calculated using the comparative threshold cycle value (Ct)
method, using the formula 2−DDCt. GAPDH was used as an in-
ternal control.
2.9. Immunoblotting
The protein concentration of liver tissue was homogenized
and extracted with TPER® mixed with Halt® protease inhibitor
cocktail (Thermo Scientiﬁc, IL, USA). The proteins were
separated using 12% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE). The proteins on the gel were
transferred onto polyvinylidene diﬂuoride membranes and
immunoblotted with anti-PPARa, PPARg, and b-actin primary
antibodies. The membranes were incubated with horseradish
peroxidase-conjugated secondary antibody, and immunoreactive
bands were developed in Clarity™Western ECL substrate (Bio-
rad, CA, USA). The band intensities were analyzed by densi-
tometry using an ImageQuant™ 400 imager (GE Healthcare
Life Science, NJ, USA).
2.10. Liver histology analysis
To determine the lipid accumulation in liver tissue, the liver
was ﬁxed in 10% neutral buffered formalin solution and
embedded in parafﬁn. The sections of about 3 mm thick were
stained with hematoxylin and eosin stain.Table 2
Body weight and organ weight of varied doses of S. alata leaf extracts in no
Organ weight (g) S. alata trea
Control 250
Body weight 40.4 ± 1.13 41.4 ± 0.32
Liver 1.61 ± 0.04 1.69 ± 0.02
Heart 0.18 ± 0.01 0.18 ± 0.01
Kidney 0.67 ± 0.02 0.66 ± 0.01
Spleen 0.12 ± 0.01 0.12 ± 0.01
The values are expressed as mean ± SEM. (n = 5). Control group received
Table 3
Body weight and organ weight of varied doses of S. alata leaf extracts in no
Organ weight (g) S. alata trea
Control 250
Body weight 38.8 ± 0.89 38.6 ± 0.99
Liver 1.56 ± 0.08 1.45 ± 0.04
Heart 0.16 ± 0.01 0.17 ± 0.01
Kidney 0.64 ± 0.02 0.60 ± 0.04
Spleen 0.11 ± 0.01 0.11 ± 0.01
The values are expressed as mean ± SEM. (n = 5). Control group received2.11. Statistical analysis
All the values were expressed as mean ± standard error of the
mean (SEM). The data were analyzed with Analysis of variance
(ANOVA) model. The differences among the groups were
assessed using Tukey's post-hoc test. A value of P < 0.05 was
considered to be statistically signiﬁcant. The statistical analyses
were performed using computer-based software SigmaStat
(Systat Software, CA, USA).
3. Results
3.1. Effect of S. alata extracts on acute toxicity test
The effect of water extract of S. alata on the general
appearance and behavioral pattern of mice are shown in Table 1.
No toxic symptoms or mortality were observed in any animals
after the administration of the extract at varied doses of 250,
500, 1000, and 2000 mg/kg for a week. In addition, no sig-
niﬁcant changes in the body weight and organ weight were
observed for all these doses (Tables 2 and 3).rmal male mice for a week.
tment group (mg/kg body weight/day)
500 1000 2000
41.8 ± 0.16 40.8 ± 0.30 41.0 ± 0.25
1.74 ± 0.05 1.66 ± 0.04 1.62 ± 0.06
0.19 ± 0.01 0.19 ± 0.01 0.19 ± 0.01
0.66 ± 0.02 0.67 ± 0.04 0.61 ± 0.02
0.12 ± 0.01 0.11 ± 0.01 0.12 ± 0.01
distilled water.
rmal female mice for a week.
tment group (mg/kg body weight/day)
500 1000 2000
39.1 ± 0.94 38.4 ± 1.12 38.1 ± 1.16
1.50 ± 0.03 1.60 ± 0.06 1.57 ± 0.06
0.18 ± 0.01 0.17 ± 0.01 0.17 ± 0.01
0.61 ± 0.01 0.64 ± 0.03 0.67 ± 0.03
0.10 ± 0.01 0.11 ± 0.01 0.10 ± 0.01
distilled water.
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weight, food intake, and energy intake
No signiﬁcant differences were observed in the initial body
weight (data not shown). After the ﬁrst six weeks of diet feeding,
the body weight of all OB groups was found to be signiﬁcantly
increased as compared with the NC group (Figure 1A). However,
at the end of the treatment period, the obese mice treated with
S. alata (250 and 500 mg/kg) did not show any signiﬁcant change
in the body weight (slightly decreased) as compared with the OB
control group (Figure 1A). No signiﬁcant difference in food intake
and energy intake was observed among the groups (Figure 1B and
C). However, the liver weight in the OB group was signiﬁcantly
increased as compared with the NC group (Figure 1D). In com-
parison with the OB control mice, the treatment with S. alata
extracts signiﬁcantly reduced the liver weight (Figure 1D).Figure 1. Body weight (A), food intake (B), energy intake (C), and liver
weight (D) in obese mice treated with S. alata leaf extract.
The values are expressed as mean ± SEM. (n = 8). #: P < 0.05 when
compared with the NC group. *: P < 0.05 when compared with the OB
group. NC: mice fed with low-fat diet, OB: mice fed with high-fat diet,
HFD + SA 250: mice fed with high-fat diet + S. alata 250 mg/kg,
HFD + SA 500: mice fed with high-fat diet + S. alata 500 mg/kg.3.3. Effect of S. alata extracts on blood glucose, serum
insulin, and serum leptin levels
The fasting blood glucose (FBG) level of the OB group was
found to be signiﬁcantly higher than the NC group (Figure 2A).
However, the treatment of S. alata (250 and 500 mg/kg)Figure 2. Fasting blood glucose (A), serum insulin (B), and serum leptin (C)
The values are expressed as mean ± SEM. (n = 8). #: P < 0.05 when compared w
fed with low-fat diet, OB: mice fed with high-fat diet, HFD + SA 250: mice fed
fat diet + S. alata 500 mg/kg.signiﬁcantly decreased the FBG as compared with the OB
group. The OB group had a high serum insulin level as
compared to the NC group (Figure 2B), whereas a signiﬁcant
reduction in insulin level was noted in the case of OB groups
treated with S. alata extracts. As shown in Figure 2C, the serum
leptin level of OB group was signiﬁcantly higher than that of the
NC group, but the obese mice treated with S. alata extracts
showed a signiﬁcant reduction in the leptin level when compared
with the OB group.
3.4. Effect of S. alata extracts on serum and hepatic lipid
proﬁles
The serum TC was signiﬁcantly increased in the OB group as
compared with the NC group (Figure 3A). The obese mice
treated with S. alata (500 mg/kg) had signiﬁcantly reduced
hypercholesterolemia as compared with the OB group. More
importantly, the high levels of serum TG and NEFA in obese
mice were markedly reduced by the treatment with S. alata
extracts (Figure 3B and C). In addition, the treatment with
S. alata signiﬁcantly decreased the TG storage in the liver tissue
(Figure 3D). In the case of liver histology, the lipid droplets
found in the OB group were more than that of the S. alata treated
OB group (Figure 3E), which was consistent with the results of
liver TG accumulation.
3.5. Effect of S. alata extracts on hepatic lipogenic gene,
and PPARa and PPARg protein expressions
The gene expressions of SREBP1c, FAS, and ACC in liver
tissue were signiﬁcantly reduced in the obese mice treated with
S. alata extracts (Figure 4A, 4B, and 4C, respectively). How-
ever, the treatment with S. alata strongly elevated the PPARa
protein expression (Figure 5A). The PPARg protein expression
was also reduced by administration with S. alata extracts
(Figure 5B) that is related to the decreased lipogenic gene
expressions.
4. Discussion
The animals in all the HFD-fed groups showed signiﬁcantly
higher body weight, dyslipidemia, and increased hepatic lipid
accumulation than those fed with LFD. These observations
conﬁrmed successful induction of obesity. Moreover, the HFD-
fed mice also had increased blood glucose, and serum insulinin obese mice treated with S. alata leaf extract.
ith the NC group. *: P < 0.05 when compared with the OB group. NC: mice
with high-fat diet + S. alata 250 mg/kg, HFD + SA 500: mice fed with high-
Figure 3. Serum total cholesterol (A), serum triglyceride (B), serum non-esteriﬁed fatty acid (C), liver triglyceride (D), and hepatic lipid accumulation
analyzed with hematoxylin and eosin staining (E) in obese mice treated with S. alata leaf extract.
For liver histological analysis, the lipid droplets were signiﬁcantly found in the obese control mice. The treatment with S. alata showed lesser lipid storage
than the obese group. The values are expressed as mean ± SEM. (n = 8). #: P < 0.05 when compared with the NC group. *: P < 0.05 when compared with
the OB group. NC: mice fed with low-fat diet, OB: mice fed with high-fat diet, HFD + SA 250: mice fed with high-fat diet + S. alata 250 mg/kg, HFD + SA
500: mice fed with high-fat diet + S. alata 500 mg/kg.
Figure 4. Gene expressions of hepatic SREBP1c (A), FAS (B), and ACC (C) in obese mice treated with S. alata leaf extract.
The values are expressed as mean ± SEM. (n = 8). #: P < 0.05 when compared with the NC group. *: P < 0.05 when compared with the OB group. NC: mice
fed with low-fat diet, OB: mice fed with high-fat diet, HFD + SA 250: mice fed with high-fat diet + S. alata 250 mg/kg, HFD + SA 500: mice fed with high-
fat diet + S. alata 500 mg/kg.
Figure 5. Protein expression of hepatic PPARa (A) and PPARg (B) in obese mice treated with S. alata leaf extract.
Values are expressed as mean ± SEM. (n = 8). #: P < 0.05 when compared with the NC group. *: P < 0.05 when compared with the OB group. NC: mice fed
with low-fat diet, OB: mice fed with high-fat diet, HFD + SA 250: mice fed with high-fat diet + S. alata 250 mg/kg, HFD + SA 500: mice fed with high-fat
diet + S. alata 500 mg/kg.
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condition. Therefore, this model is well suitable for examining
the lipid-lowering effects of S. alata leaf extract in HFD-induced
obese ICR mice.
We ﬁrst examined the alterations in body weight and food
consumption and found that the treatment with S. alata extracts
slightly reduced the body weight gain but increased the food
consumption and energy intake. Although the body weight and
food intake did not show any signiﬁcant difference in the obese
groups, the weight of liver tissue in OB mice treated with
S. alata extracts was markedly decreased as compared to the OB
mice. These results are interesting as they show the effect of
S. alata extract in regulating the metabolic parameters in the
liver tissue. We further examined the lipid proﬁles in serum and
liver tissue and found that S. alata extracts effectively reduced
the serum TC, TG, and NEFA as well as decreased the hepatic
TG accumulation. The decrease in the serum lipid proﬁles may
be associated with inhibited cholesterol absorption in the small
intestine, stimulated lipid storage in fat tissue, and suppressed
TG and NEFA concentrations in serum and liver [19,20]. The
liver plays a major role in lipid metabolism. The dietary HFD
consumption can increase the liver weight due to TG
accumulation [21]. The present study showed that the treatment
of S. alata extracts could reduce the liver weight. This may be
supported by the decreased TG accumulation. Moreover, the
lipid droplets in the liver histological examination were clearly
decreased in obese mice treated with S. alata extracts. These
results may indicate that the S. alata extracts had a potential
effect in the regulation of lipid metabolism in obese mice.
The increased fatty acid synthesis and decreased fatty acid
oxidation are the two important factors responsible for the
accumulation of TG in the hepatocytes. PPARa is an important
nuclear receptor in controlling lipid metabolism [22]. The
stimulation of fatty oxidation and reduction of circulating TG
are the key characters of PPARa agonist [23,24]. The present
study showed that the extracts of S. alata signiﬁcantly
increased PPARa protein expression. This suggested that
S. alata extracts can also reduce the hepatic TG storage via
stimulating the PPARa action. Moreover, the increase in the
gene expression of SREBP1c transcription factor was found in
the OB group, which is responsible for enhancing the activity
of lipogenic enzyme genes such as FAS and ACC.
Interestingly, a signiﬁcant decrease in the gene expressions of
SREBP1c, FAS, and ACC with S. alata treatment were
observed in this study. The activation of PPARg is also
related to increased fatty liver state [10]. This study showed a
decline in the protein expression of PPARg in obese mice
treated with S. alata extracts. Therefore, the lowered hepatic
TG level after the treatment with S. alata extract in HFD-fed
mice seems to be related to the decreased expression of the
transcriptional factors such as SREBP1c and PPARg. This in
turn inhibited the gene expressions of lipogenic enzymes such as
ACC and FAS, thus, resulting in the inhibition of the accumu-
lation of TG in the liver tissues.
The insulin resistance is a well-characterized system for
T2DM development. The leptin level is an adipokine indicator
that needs to be elevated in the dietary obese rodents [25]. An
improvement in the insulin resistance and hyperglycemia is
observed by the modiﬁcation of hepatic fatty acid
composition [26]. The present study showed that the HFD-fed
mice could induce the condition of insulin resistance. Howev-
er, the insulin resistance was ameliorated in S. alata treatedgroups by a marked reduction of hyperinsulinemia, hypergly-
cemia, and hyperleptinemia. These results suggested that the
treatment may improve the insulin resistance in HFD-induced
obese mice.
In conclusion, the administration of S. alata extract improved
the abnormalities in the lipid metabolism in HFD-induced obese
mice by the reduction of serum lipid proﬁles and hepatic TG
content, stimulation of PPARa protein expression, and sup-
pression of SREBP1c, FAS and ACC genes, and PPARg protein
expressions. With the inhibition of hepatic lipid accumulation,
the insulin resistance could be improved and the high blood
glucose, insulin and leptin levels were decreased. These ﬁndings
are the ﬁrst report to show the potential effects of S. alata leaf
extract on the abnormal lipid metabolism in such obesity
condition.Conﬂict of interest statement
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